Journal of cancer policy · 2026
National trends in lung cancer stage, treatment, and time to treatment initiation after a major healthcare disruption (NCDB 2014-2022).
СтатьяПоддержка исследования: вне правительства СШАНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Diaz Collante Javier, Crawford Allison, Reddington Hayley, Markel Arianna, Epstein Mara, Gray Catherine, Lou Feiran, Phillips William, Maxfield Mark, Uy Karl, Emmerick Isabel
Аннотация
INTRODUCTION: Healthcare system (HCS) disruptions during COVID-19 have significantly impacted cancer diagnostics and treatment management. This study examined the effects of the COVID-19 pandemic on the staging at diagnosis, initial treatment patterns, and time to treatment initiation (TTI) for non-small cell lung cancer (NSCLC), focusing on disparities across healthcare settings and demographics.
METHODS: We conducted a retrospective cohort analysis of NSCLC cases in the US National Cancer Database (2014-2022), excluding records with missing TTI or clinical stage data. Outcomes were compared before (2014-2019) and after (2021-2022) the healthcare system disruption using chi-square tests, t-tests, and interrupted time series analysis.
RESULTS: A total of 865,808 individuals were included (mean age 69; 50% female; 82% White; 73% Medicare/Medicaid). Early-stage diagnoses increased from 44% to 46% (p < 0.01). Minor differences were observed in initial treatment patterns. Mean TTI increased by approximately 9 days (p < 0.01), with community cancer programs showing the greatest increase (+10 days) compared to other facilities. Regional differences were also noted, with New England experiencing the highest TTI increase (+12 days). Black individuals faced longer TTIs (56 vs 51 days for White patients), though White patients experienced the greatest increased (+9 days).
CONCLUSIONS: Healthcare system disruptions due to COVID-19 were associated with delayed NSCLC diagnoses, longer treatment initiation, and persistent disparities in access to timely care. While short-term survival differences were modest, earlier treatment initiation remained associated with improved outcomes. Further research is needed to evaluate whether these delays persist and to explore their long-term consequences on patient outcomes.
POLICY SUMMARY: This evidence calls for resilience-focused oncology policies, supporting continuity plans, real-time delay monitoring, and targeted resource allocation to underserved and outpatient settings.
METHODS: We conducted a retrospective cohort analysis of NSCLC cases in the US National Cancer Database (2014-2022), excluding records with missing TTI or clinical stage data. Outcomes were compared before (2014-2019) and after (2021-2022) the healthcare system disruption using chi-square tests, t-tests, and interrupted time series analysis.
RESULTS: A total of 865,808 individuals were included (mean age 69; 50% female; 82% White; 73% Medicare/Medicaid). Early-stage diagnoses increased from 44% to 46% (p < 0.01). Minor differences were observed in initial treatment patterns. Mean TTI increased by approximately 9 days (p < 0.01), with community cancer programs showing the greatest increase (+10 days) compared to other facilities. Regional differences were also noted, with New England experiencing the highest TTI increase (+12 days). Black individuals faced longer TTIs (56 vs 51 days for White patients), though White patients experienced the greatest increased (+9 days).
CONCLUSIONS: Healthcare system disruptions due to COVID-19 were associated with delayed NSCLC diagnoses, longer treatment initiation, and persistent disparities in access to timely care. While short-term survival differences were modest, earlier treatment initiation remained associated with improved outcomes. Further research is needed to evaluate whether these delays persist and to explore their long-term consequences on patient outcomes.
POLICY SUMMARY: This evidence calls for resilience-focused oncology policies, supporting continuity plans, real-time delay monitoring, and targeted resource allocation to underserved and outpatient settings.